Prophase Labs (PRPH) AI Stock Analysis

• Market Cap: $12.12M
• Dividend Yield: N/A
• Average Volume (3M): 2.72M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 41,541,206
• 10 Day Avg. Volume: 1,358,998
• 30 Day Avg. Volume: 2,724,170
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 2.13
• P/FCF Ratio: -0.78
• Enterprise Value/Market Cap: 1.98
• Enterprise Value/Revenue: 7.17
• Enterprise Value/Gross Profit: 11.86
• Enterprise Value/Ebitda: -0.91
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.50 ▲(78.57% Upside)

Prophase Labs' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative profitability. Technical analysis indicates bearish momentum, and valuation metrics reflect financial distress. While the earnings call provided some optimism with potential cash recovery and new ventures, these are offset by current financial and market concerns.

Prophase Labs Business Overview & Revenue Model

Company Description

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

How the Company Makes Money

Prophase Labs generates revenue through several key streams, including the sale of its proprietary diagnostic products, therapeutic solutions, and any associated licensing agreements. The company may also form strategic partnerships with other biotech firms, healthcare providers, or research institutions to co-develop products or services, which can lead to additional revenue through collaboration fees or shared profits. Additionally, Prophase Labs may receive funding from government grants or private investments aimed at supporting research and development initiatives, further contributing to its overall earnings.

Prophase Labs Financial Statement Overview

Summary

Prophase Labs faces significant financial challenges, with declining revenues and negative profitability metrics. The balance sheet shows moderate leverage but poor returns on equity. Cash flow issues persist, with negative operating and free cash flows. The company needs to address revenue volatility and improve operational efficiency to enhance financial stability.

Income Statement

Prophase Labs has experienced significant revenue decline, with a TTM revenue growth rate of -26.87%. The company also shows negative profitability margins, including a net profit margin of -12.41% and an EBIT margin of -9.58%, indicating challenges in maintaining profitability. Historical data shows a peak in revenue in 2022, followed by a steep decline, highlighting volatility in revenue streams.

Balance Sheet

The balance sheet reflects moderate leverage with a TTM debt-to-equity ratio of 0.48, which is an improvement from the previous year's 3.34. However, the return on equity is significantly negative at -230.18%, indicating poor returns for shareholders. The equity ratio stands at 27.21%, suggesting a moderate reliance on equity financing.

Cash Flow

Cash flow analysis reveals negative operating cash flow and free cash flow, with a TTM free cash flow growth rate of -39.87%. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Despite this, the free cash flow to net income ratio is close to 1, indicating that free cash flow is nearly equivalent to net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.34M	6.77M	44.38M	122.65M	79.04M	14.51M
Gross Profit	2.02M	-150.00K	16.24M	70.65M	32.81M	4.61M
EBITDA	-26.18M	-32.34M	-14.83M	28.73M	11.39M	-1.49M
Net Income	-41.45M	-53.36M	-16.78M	18.46M	6.27M	-2.13M
Balance Sheet
Total Assets	42.04M	63.20M	91.93M	87.65M	89.30M	31.41M
Cash, Cash Equivalents and Short-Term Investments	171.00K	678.00K	4.74M	17.44M	17.26M	8.46M
Total Debt	5.54M	24.57M	21.38M	6.96M	14.90M	14.72M
Total Liabilities	30.61M	55.85M	42.54M	24.02M	30.67M	20.85M
Stockholders Equity	11.44M	7.35M	49.38M	63.63M	58.63M	10.56M
Cash Flow
Free Cash Flow	-6.03M	-18.44M	-14.50M	24.63M	-17.85M	-4.28M
Operating Cash Flow	-6.09M	-17.54M	-11.35M	28.55M	-13.62M	-2.59M
Investing Cash Flow	783.00K	2.42M	-1.37M	-2.08M	-19.67M	-1.02M
Financing Cash Flow	8.79M	14.19M	5.76M	-26.02M	35.13M	9.99M

Prophase Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPH, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.43, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 30.93 is Neutral, neither overbought nor oversold. The STOCH value of 8.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRPH.

Prophase Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	50 Neutral	$21.11M	-0.76	-60.76%	―	-18.05%	33.87%
TXMD	47 Neutral	$13.54M	-29.32	-1.98%	―	156.93%	92.75%
PRPH	45 Neutral	$12.12M	-0.19	―	―	―	―
YCBD	40 Underperform	$7.21M	-0.13	-33.13%	―	-7.80%	90.17%
IMCC	38 Underperform	$6.72M	-2.36	-36.94%	―	2.17%	88.34%
FLGC	38 Underperform	$6.77M	-0.23	-37.38%	―	-22.60%	53.82%

Prophase Labs Corporate Events

ProPhase Labs Signs Sales Agreement with WestPark Capital

On October 9, 2025, ProPhase Labs, Inc. entered into an At-the-Market Sales Agreement with WestPark Capital, Inc., allowing the company to offer and sell shares of its common stock through the agent. This agreement, underpinned by the company’s effective registration statement and related prospectus, provides ProPhase Labs with flexibility in its stock offerings, potentially impacting its market presence and financial strategy. The agreement includes customary provisions and allows for termination by either party, reflecting a strategic move to manage its capital and shareholder interests.

The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

ProPhase Labs Partners with ThinkEquity for $6M Placement

On September 12, 2025, ProPhase Labs entered into a Strategic Advisory and Private Placement Agreement with ThinkEquity LLC to serve as its exclusive strategic advisor, placement agent, and investment banker. The agreement involves a proposed private placement of approximately $6 million in securities, with ThinkEquity receiving compensation in cash and warrants. This strategic move is part of ProPhase Labs’ digital asset treasury strategy, potentially impacting its operations and market positioning by involving significant crypto asset accumulation and board representation rights for ThinkEquity.

The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

Prophase Labs Approves Strategic Amendments at Special Meeting

On September 9, 2025, ProPhase Labs held a Special Meeting of Stockholders where 63.54% of shares were voted. The stockholders approved several proposals including amendments to equity compensation plans, an increase in authorized shares, a share repurchase program, and changes to the company’s bylaws, indicating strategic adjustments to enhance operational flexibility and shareholder value.

The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

ProPhase Labs Earnings Call: Balancing Optimism and Challenges

ProPhase Labs’ recent earnings call painted a picture of both optimism and caution, reflecting a balance between promising future prospects and current financial hurdles. The company is poised for potential growth through strategic initiatives, yet faces challenges with stock performance and financial stability.

Prophase Labs Ends Stock Purchase Agreement with Keystone

On August 27, 2025, ProPhase Labs, Inc. announced the termination of its Common Stock Purchase Agreement with Keystone Capital Partners, LLC, which was initially established on January 29, 2025. This agreement allowed ProPhase Labs to sell shares of its common stock to Keystone up to approximately $7.7 million. The termination, effective August 28, 2025, was executed at the company’s discretion without any penalties or fees, and there are no other material relationships between the two entities.

The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

Prophase Labs Files Proxy, Reschedules Shareholder Meeting

On August 19, 2025, ProPhase Labs announced the filing of a definitive proxy statement with the SEC and received a ‘no further comments’ letter, indicating the completion of the SEC’s review. The Special Meeting of Shareholders was rescheduled to September 9, 2025, to ensure proper dissemination of proxy materials. The Board recommends shareholders vote ‘FOR’ proposals aimed at strategic growth, including increasing authorized shares and a $15 million share repurchase program. These initiatives are intended to support the company’s crypto treasury strategy, attract major industry partners, and enhance financial flexibility, potentially increasing long-term shareholder value.

The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

ProPhase Labs Reports Turnaround and Strategic Growth

ProPhase Labs Inc. is a diversified company operating in the biotech, genomics, and consumer healthcare sectors, known for its innovative diagnostics and consumer health products. In its latest earnings report, ProPhase Labs announced significant operational and financial improvements for the three and six months ending June 30, 2025, highlighting a strategic shift towards non-dilutive liquidity initiatives and transformational growth catalysts.

ProPhase Labs Achieves Key U.S. Patent for Test

ProPhase Labs reported significant financial and operational improvements for the first half of 2025, including a strengthened equity position and reduced liabilities. The company achieved a key U.S. patent for its BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test, positioning it for faster market entry. Additionally, ProPhase streamlined its operations, reduced costs, and improved margins, setting a path for future growth. The company is also exploring a strategic treasury initiative involving digital assets to complement its core businesses.

ProPhase Labs Appoints New Fractional CFO

ProPhase Labs, Inc. announced the resignation of its Chief Operating Officer, Stu Hollenshead, effective July 31, 2025, who will transition to a marketing consultant role. The company is searching for a successor, with interim duties managed by the executive team. Additionally, ProPhase Labs appointed Steven M. Plumb as its fractional Chief Financial Officer on August 6, 2025. Plumb, a seasoned financial executive, will provide operational advice and oversee SEC filings, while CEO Ted Karkus remains the principal financial officer.